Cagrilintide vs Retatrutide
Metabolic
Cagrilintide
Long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism.
Metabolic
Retatrutide
Triple agonist at GIP, GLP-1, and glucagon receptors — among the most actively studied compounds in current metabolic research.
Side by side
| Dimension | Cagrilintide | Retatrutide |
|---|---|---|
| Molecular weight | 4409 g/mol | 4731.32 g/mol |
| Size class | long peptide | long peptide |
| CAS number | 1415456-99-3 | 2381089-83-2 |
| Research area | metabolic | metabolic |
| Sequence | Not published as a linear sequence | Not published as a linear sequence |
| Available sizes | 10mg | 10mg, 20mg, 30mg |
| Entry price | $99 | $99 |
| Cost per mg | $9.90 | $7.47 |
Mechanism
Cagrilintide
Cagrilintide is an acylated analog of human amylin, the peptide co-secreted with insulin from pancreatic β-cells. It acts at the calcitonin receptor and amylin receptor subtypes, a pathway entirely separate from GLP-1 and GIP signaling. Research interest centers on whether amylin and incretin pathways are additive, which is why it appears frequently in combination studies alongside semaglutide.
Retatrutide
Retatrutide is a single-molecule triple agonist acting at the GIP, GLP-1, and glucagon receptors. The inclusion of glucagon receptor agonism is mechanistically distinct from dual agonists: glucagon receptor activation is studied for effects on hepatic lipid handling and energy expenditure, pathways not engaged by incretin agonism alone. It remains investigational and is a frequent subject of comparative receptor-pharmacology work.
Evidence quality
Mechanism is not the same as evidence. Where we have assessed the literature, the verdict is stated plainly.
Cagrilintide
Evidence base: strong and independently reported. Randomised phase 2 and phase 3 data in major journals, with a trial design that compares the combination against each component separately.
Full research reference →Retatrutide
Evidence base: emerging. Receptor pharmacology characterized; long-term and independent replication limited by the compound's investigational status.
Full research reference →Research applications
Cagrilintide
- Amylin and calcitonin receptor binding studies
- Combination pharmacology with incretin agonists
- Satiety signaling research in preclinical models
- Gastric emptying rate assays
Retatrutide
- Triple receptor agonism and pathway-contribution studies
- Hepatic lipid metabolism research in preclinical models
- Energy expenditure and thermogenesis pathway assays
- Head-to-head comparison against dual agonists
Common questions
What is the difference between Cagrilintide and Retatrutide?
Cagrilintide is long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism. Retatrutide is triple agonist at GIP, GLP-1, and glucagon receptors — among the most actively studied compounds in current metabolic research. They differ in molecular weight (4409 vs 4731.32 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, Cagrilintide or Retatrutide?
Retatrutide is lower at approximately $7.47 per milligram at its best tier, against $9.90 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can Cagrilintide and Retatrutide be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should Cagrilintide and Retatrutide be stored?
Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days. For Retatrutide: Store lyophilized powder at -20°C protected from light. Reconstituted solution stable at 2-8°C for up to 30 days.
Which has the stronger evidence base?
Cagrilintide — Evidence base: strong and independently reported. Randomised phase 2 and phase 3 data in major journals, with a trial design that compares the combination against each component separately. Retatrutide — Evidence base: emerging. Receptor pharmacology characterized; long-term and independent replication limited by the compound's investigational status.
All products sold on this website are intended for research and identification purposes only. These products are not intended for human dosing, injection, or ingestion.
Comparison generated from Lyra Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.